Autoimmune CAR-T Faces Tough Questions After Novartis, Bristol Myers Study Halts

Autoimmune CAR-T faces tough questions after Novartis, Bristol Myers study halts

Wall Street analysts believe that a more cautious approach to manufacturing, study enrollment and side effect management could help developers avoid future safety hazards.

Pharmalittle: We're reading about Novartis and Bristol pausing cell therapy trials, a $480K cancer drug, and more

Today's pharma news includes Novartis and Bristol halting cell therapy trials against autoimmune conditions after observing inflammatory side effects in testing.

UPDATED: Novartis halts autoimmune CAR-T trials after 3 deaths, as BMS also pauses studies

The Entire Business World on a Single Page with the Web's Most Comprehensive One-Stop Finance News Hub.

Novartis, Bristol Myers Pause Autoimmune CAR-T Trials Over Safety Concerns: Report

Novartis suspends eight autoimmune trials of its CAR-T therapy Rap-cel after three cases of fatal outcomes, while Bristol Myers Squibb voluntarily pauses enrollment in its Zola-cel autoimmune studies over transient inflammatory events.